换一批
换一批Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
作者：
主题词
成年人(Adult);老年人(Aged);抗肿瘤药(Antineoplastic Agents);癌, 肾细胞(Carcinoma, Renal Cell);综合疗法(Combined Modality Therapy);疾病恶化(Disease Progression);女(雌)性(Female);人类(Humans);免疫疗法(Immunotherapy);白细胞介素2(Interleukin-2);肾肿瘤(Kidney Neoplasms);淋巴细胞计数(Lymphocyte Count);淋巴细胞, 肿瘤浸润(Lymphocytes, Tumor-Infiltrating);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);预后(Prognosis);受体, 抗原, T细胞, γ-δ(Receptors, Antigen, T-Cell, gamma-delta);存活率(Survival Rate);T淋巴细胞(T-Lymphocytes)
DOI
10.1007/s00262-008-0491-8
PMID
18301889
发布时间
2024-04-26
- 浏览7
Cancer immunology, immunotherapy
1599-609页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
